PGPatrick J. Grohar

Patrick J. Grohar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patrick J. Grohar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Lee J. Helman

    Authors' Affiliations: 1Monroe Carrell Jr. Children's Hospital at Vanderbilt and the Vanderbilt Ingram Cancer Center, Nashville, Tennessee; 2Molecular Oncology Section, Pediatric Oncology Branch; 3Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and 4Istituto di Ricerche Farmacologiche “Mario Negri” -IRCCS, Milan, Italy

    2 shared publications
  • Arnulfo Mendoza

    Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

    1 shared publication
  • Choh Yeung

    Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

    1 shared publication
  • Laure E. Segars

    Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

    1 shared publication
  • Maurizio D'Incalci

    Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

    1 shared publication
  • Yves Pommier

    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD

    1 shared publication

Latest Publications

  • Open Access

    Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth

    by Patrick J. Grohar, Laure E. Segars, Choh Yeung, Yves Pommier, Maurizio D'Incalci, Arnulfo Mendoza, Lee J. Helman

    Purpose: The goal of this study is to optimize the activity of trabectedin for Ewing sarcoma by developing a molecularly targeted combination therapy. Experimental Design: We have recently shown that trabectedin interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. In this report, we build on this work to develop a trabectedin-based combination therapy with improved EWS-FLI1 suppression that also targets the drug-associated DNA damage to Ewing sarcoma cells. Results: We demonstrate by siRNA experiments that EWS-FLI1 drives the expression of the Werner syndrome protein (WRN) in Ewing sarcoma cells. Because WRN-deficient cells are known to be hypersensitive to camptothecins, we utilize trabectedin to block EWS-FLI1 activity, suppress WRN expression, and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38. We show that trabectedin and SN38 are synergistic, demonstrate an increase in DNA double-strand breaks, an accumulation of cells in S-phase and a low picomolar IC50. In addition, SN38 cooperates with trabectedin to augment the suppression of EWS-FLI1 downstream targets, leading to an improved therapeutic index in vivo. These effects translate into the marked regression of two Ewing sarcoma xenografts at a fraction of the dose of camptothecin used in other xenograft studies. Conclusions: These results provide the basis and rationale for translating this drug combination to the clinic. In addition, the study highlights an approach that utilizes a targeted agent to interfere with an oncogenic transcription factor and then exploits the resulting changes in gene expression to develop a molecularly targeted combination therapy. Clin Cancer Res; 20(5); 1190–203. ©2013 AACR.